Expression of ESYT3 and FNDC1 in lung adenocarcinoma and their relationship with tumor progression
Objective To detect the expression of extended synaptic binding protein 3(ESYT3)and type Ⅲ fibronectin do-main-containing protein 1(FNDC1)in lung adenocarcinoma patients,and to analyze their relationship with tumor progres-sion.Methods Pathological tissue specimens of 137 patients with lung adenocarcinoma admitted to Henan Chest Hospital from June 1,2019 to June 1,2022 were included.There were 96 males and 41 females.The average age was(65.87±8.14)years,ranging from 43 to 76 years.Immunohistochemical staining was used to detect the positive expression of ESYT3 and FNDC1 proteins in cancer tissues and adjacent tissues(≥3 cm from cancer tissues),and to analyze the relationship between the positive expression of ESYT3 and FNDC1 and clinicopathological features.The patients were followed up until October 1,2023 to compare the positive expression of ESYT3 and FNDC1 in cancer tissues of patients with different progression.x2 test was used to analyze the relationship between ESYT3 and FNDC1 positive expression and clinicopathological features of lung adenocarcinoma.Multi-factor Cox proportional risk regression model was used to analyze the influencing factors of lung adenocarcinoma progression,and Kaplan-Meier curve was plotted to analyze the re-lationship between ESYT3 and FNDC1 protein expression in cancer tissue and lung adenocarcinoma progression.Results The positive expression rates of ESYT3 and FNDC1 were 33.58％(46/137)and 56.20％(77/137)respectively in lung adenocarcinoma tissues and adjacent tissues,and the positive expression rates of FNDC1 were 43.07％(59/137)and 21.90％(30/137),respectively,with statistically significant differences,x2 value being 14.177 and 13.995,respec-tively,both P＜0.001.The ESYT3 positive expression rate of patients with smoking history,TNM stage Ⅲ,lymph node metastasis,undifferentiated/poorly differentiated,and pleural invasion was lower than that of patients with no smoking history(x2=7.344,P=0.007),TNM stage Ⅰ/Ⅱ(x2=7.766,P=0.005),and no lymph node metastasis(x2=7.161,P=0.007),moderately/highly differentiated(x2=6.742,P=0.009),and no pleural invasion(x2=8.408,P=0.004);the positive expression rate of FNDC1 in cancer tissues was higher than that in patients with no his-tory of smoking(x2=9.352,P=0.002),TNM stage Ⅰ/Ⅱ(x2=6.691,P=0.010),and no lymph node metastasis(x2=4.258,P=0.039),moderately/highly differentiated(x2=7.421,P=0.006),and no pleural invasion(x2=7.738,P=0.005).The follow-up period ranged from 16 to 52 months,with a median follow-up time of 37(18,48)months.The progression rate of 124 patients was 50.81％(63/124).Multivariate Cox proportional hazard regression model analysis showed that smoking history(HR=3.254,95％CI:1.339-7.908),TNM stage Ⅲ(HR=2.125,95％CI:1.279-3.531),no/low differentiation(HR=2.032,95％CI:1.230-3.356),FNDC1 expression(HR=2.980,95％CI:1.570-5.657)were risk factors for the progression of lung adenocarcinoma,and ESYT3 expression(HR=0.961,95％CI:0.940-0.983)was a protective factor.The progression-free survival(PFS)of patients with posi-tive and negative ESYT3 protein expression was 51(95％CI:41.594-60.406)and 43(95％CI:35.335-50.665)months,respectively,and the difference was statistically significant(x2=6.294,P=0.012).The PFS of patients with positive and negative FNDC1 protein expression was 39(95％CI:32.350-45.650)and 48(95％CI:44.760-51.240)months,respectively,and the difference was statistically significant(x2=8.075,P=0.004).Conclusion The low ex-pression of ESYT3 and high expression of FNDC1 in lung adenocarcinoma are related to smoking history,TNM stage,lymph node metastasis,tissue differentiation degree and pleural invasion,and they are influencing factors for the progres-sion of lung adenocarcinoma.
lung adenocarcinomaextended synaptotagmin 3(ESYT3)fibronectin type Ⅲ domain-containing protein 1(FNDC1)tumor progression
NETL
NSTL
万方数据
